Pharmaceutical intermediates
Tazemetostat Hydrobromide Intermediates
9 pharmaceutical intermediates for Tazemetostat Hydrobromide. Indication: Follicular Lymphoma; Sarcoma.
About Tazemetostat Hydrobromide
- Originator
- Epizyme Inc
- Indication
- Follicular Lymphoma; Sarcoma
- Approved Date
- 01/23/2020
- NCE Patent
- 01/23/2025
- DS/DP
- 09/12/2031
Available intermediates
9 intermediates currently listed for Tazemetostat Hydrobromide. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 5-Bromo-2-methyl-3-nitrobenzoic acid | 107650-20-4 | / | / |
| Methyl 5-bromo-2-methyl-3-nitrobenzoate | 220514-28-3 | / | / |
| Methyl 3-amino-5-bromo-2-methylbenzoate | 1000342-11-9 | / | / |
| [1,1'-Biphenyl]-3-carboxylic acid, 5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, methyl ester | 1403258-99-0 | / | / |
| [1,1'-Biphenyl]-3-carboxylic acid, 5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)- | 1403259-00-6 | / | / |
| 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine | 364794-79-6 | / | / |
| 3-(aminomethyl)-4,6-dimethyl-1,2-dihydropyridin-2-one hydrochloride | 1173081-96-3 | / | / |
| Methyl 5-bromo-2-methyl-3-((tetrahydro-2H-pyran-4-yl)amino)benzoate | 1403257-49-7 | / | / |
| Methyl 5-bromo-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzoate | 1403257-79-3 | / | / |
Building toward Tazemetostat Hydrobromide?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →